Hypersensitivity to inhaled TOBI ®  following reaction to gentamicin | Zendy

Spigarelli Michael G. | Zendy; Hurwitz Martin E. | Zendy; Nasr Samya Z. | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

Hypersensitivity to inhaled TOBI ® following reaction to gentamicin

Author(s) -

Spigarelli Michael G.,

Hurwitz Martin E.,

Nasr Samya Z.

Publication year - 2002

Publication title -

pediatric pulmonology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.866

H-Index - 106

eISSN - 1099-0496

pISSN - 8755-6863

DOI - 10.1002/ppul.10049

Subject(s) - medicine , rash , discontinuation , inhalation , tobramycin , cystic fibrosis , gentamicin , desensitization (medicine) , hypersensitivity reaction , pseudomonas aeruginosa , antibiotics , anesthesia , dermatology , immunology , microbiology and biotechnology , genetics , receptor , bacteria , biology

Cystic fibrosis (CF) is the most common autosomal‐recessive disease in Caucasians. Colonization with Pseudomonas aeruginosa ( P. aeruginosa ) of the CF airways causes deterioration of pulmonary status. TOBI ® (Tobramycin solution for inhalation) is an inhaled antibiotic that can improve the pulmonary disease. We report on a 9‐year old boy with CF who developed a rash following a course of IV gentamicin. The rash resolved after its discontinuation. However, the rash returned all over his body, with the start of inhalation of TOBI ® therapy. We desensitized the patient using escalating doses of inhaled TOBI ® . He tolerated the procedure well, and continues to be on TOBI ® 9 months after desensitization on a once‐a‐day regimen. Pediatr Pulmonol. 2002; 33:311‐314. © 2002 Wiley‐Liss, Inc.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research